Trial
NCT05018975
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
Phase IIWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
Loma Linda University
Collaborators
—
Condition
COVID-19 Acute Respiratory Distress Syndrome
Intervention
Tazemetostat
Why stopped
FDA recommendation cited safety issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-22